This company listing is no longer active
CloudMD Software & Services Croissance future
Future contrôle des critères 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for CloudMD Software & Services.
Informations clés
n/a
Taux de croissance des bénéfices
n/a
Taux de croissance du BPA
| Healthcare croissance des bénéfices | 63.3% |
| Taux de croissance des recettes | n/a |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | None |
| Dernière mise à jour | n/a |
Mises à jour récentes de la croissance future
Recent updates
CloudMD Software & Services Inc. (CVE:DOC) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Mar 08
CloudMD Software & Services Inc.'s (CVE:DOC) 28% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Oct 21Is CloudMD Software & Services (CVE:DOC) Weighed On By Its Debt Load?
Jan 12Is Now The Time To Look At Buying CloudMD Software & Services Inc. (CVE:DOC)?
Aug 09CloudMD Software & Services Inc.'s (CVE:DOC) Intrinsic Value Is Potentially 39% Above Its Share Price
Jun 20Is CloudMD Software & Services (CVE:DOC) Using Debt In A Risky Way?
May 04Is CloudMD Software & Services (CVE:DOC) A Risky Investment?
Jan 20Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme CloudMD Software & Services n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.
Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.
Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 3/31/2024 | 91 | -74 | -11 | -9 | N/A |
| 12/31/2023 | 91 | -77 | -14 | -12 | N/A |
| 9/30/2023 | 91 | -24 | -10 | -18 | N/A |
| 6/30/2023 | 92 | -108 | -7 | -13 | N/A |
| 3/31/2023 | 95 | -114 | -17 | -23 | N/A |
| 12/31/2022 | 99 | -112 | -22 | -28 | N/A |
| 9/30/2022 | 105 | -112 | -32 | -27 | N/A |
| 6/30/2022 | 111 | -28 | -40 | -36 | N/A |
| 3/31/2022 | 89 | -23 | -31 | -28 | N/A |
| 12/31/2021 | 70 | -24 | -25 | -22 | N/A |
| 9/30/2021 | 48 | -23 | -21 | -20 | N/A |
| 6/30/2021 | 22 | -21 | -14 | -13 | N/A |
| 3/31/2021 | 21 | -17 | -11 | -10 | N/A |
| 12/31/2020 | 15 | -14 | -9 | -8 | N/A |
| 9/30/2020 | 12 | -8 | -5 | -5 | N/A |
| 6/30/2020 | 10 | -7 | -3 | -3 | N/A |
| 3/31/2020 | 9 | -5 | -2 | -2 | N/A |
| 12/31/2019 | 7 | -5 | -2 | -2 | N/A |
| 9/30/2019 | 5 | -5 | -2 | -2 | N/A |
| 6/30/2019 | 3 | -5 | -3 | -3 | N/A |
| 3/31/2019 | 2 | -4 | -2 | -2 | N/A |
| 12/31/2018 | 1 | -3 | -1 | -1 | N/A |
| 9/30/2018 | 0 | -1 | -1 | -1 | N/A |
| 6/30/2018 | N/A | -1 | 0 | 0 | N/A |
| 3/31/2018 | N/A | -1 | 0 | 0 | N/A |
| 12/31/2017 | N/A | 0 | N/A | 0 | N/A |
| 9/30/2017 | 0 | 0 | N/A | 0 | N/A |
| 6/30/2017 | 0 | 0 | N/A | 0 | N/A |
| 3/31/2017 | N/A | -2 | N/A | 0 | N/A |
| 12/31/2016 | N/A | -2 | N/A | 0 | N/A |
| 9/30/2016 | 0 | -2 | N/A | 0 | N/A |
| 6/30/2016 | 0 | -2 | N/A | 0 | N/A |
| 3/31/2016 | N/A | 0 | N/A | 0 | N/A |
| 12/31/2015 | N/A | 0 | N/A | 0 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if DOC's forecast earnings growth is above the savings rate (2.1%).
Bénéfices vs marché: Insufficient data to determine if DOC's earnings are forecast to grow faster than the Canadian market
Croissance élevée des bénéfices: Insufficient data to determine if DOC's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: Insufficient data to determine if DOC's revenue is forecast to grow faster than the Canadian market.
Croissance élevée des revenus: Insufficient data to determine if DOC's revenue is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if DOC's Return on Equity is forecast to be high in 3 years time